Trial Profile
Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Remtolumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 29 Oct 2018 Results characterizing exposure-response relationships for ABT-122 relative to adalimumab (TNF-alpha inhibitor) using ABT-122 phase 2 trials (NCT02433340, NCT02349451) published in the Rheumatology
- 18 Jul 2018 Results published in the Rheumatology
- 31 May 2016 Status changed from active, no longer recruiting to completed.